| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
61,413,000 |
| Market
Cap: |
9.16(B) |
| Last
Volume: |
875,140 |
Avg
Vol: |
504,506 |
| 52
Week Range: |
$114.17 - $208.42 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. Co.'s bioprocessing business is comprised of:Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and Proteins, which are represented by its Protein A affinity ligands and cell culture growth factor products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$238,260 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
40,296 |
45,669 |
50,307 |
151,828 |
| Total Sell Value |
$7,357,263 |
$8,416,817 |
$9,119,818 |
$30,980,273 |
| Total People Sold |
2 |
4 |
5 |
6 |
| Total Sell Transactions |
3 |
5 |
7 |
17 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ryan Thomas F Jr |
Director |
– • – |
2021-03-12 |
4 |
GD |
$0.00 |
$0 |
D/D |
170 |
1,294 |
|
- |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2021-03-12 |
4 |
AS |
$188.06 |
$1,732,847 |
D/D |
(9,102) |
212,762 |
|
6% |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2021-03-10 |
4 |
S |
$190.08 |
$1,523,501 |
D/D |
(8,000) |
25,265 |
|
-8% |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2021-03-10 |
4 |
OE |
$33.05 |
$273,168 |
D/D |
8,000 |
33,265 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2021-03-04 |
4 |
S |
$190.06 |
$398,396 |
D/D |
(2,075) |
25,265 |
|
-6% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2021-03-04 |
4 |
S |
$185.22 |
$4,165,091 |
D/D |
(21,900) |
221,864 |
|
-6% |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2021-03-04 |
4 |
S |
$189.75 |
$682,295 |
D/D |
(3,545) |
32,363 |
|
-6% |
|
| Ryan Thomas F Jr |
Director |
– • – |
2021-03-03 |
4 |
S |
$205.00 |
$205,000 |
D/D |
(1,000) |
1,464 |
|
-0% |
|
| Ryan Thomas F Jr |
Director |
– • – |
2021-03-03 |
4 |
OE |
$26.12 |
$26,120 |
D/D |
1,000 |
2,464 |
|
- |
|
| Gebski Christine |
See RemarksOfficer |
• – – |
2021-02-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
38,540 |
|
-0% |
|
| Bylund James |
SVP, Global Operations & ITOff |
• – – |
2021-02-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,684 |
|
-0% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
10,437 |
243,764 |
|
- |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
1,686 |
27,340 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2021-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
2,410 |
35,908 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2021-01-25 |
4 |
OE |
$33.87 |
$135,480 |
D/D |
4,000 |
33,498 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2021-01-04 |
4 |
AS |
$188.69 |
$757,840 |
D/D |
(3,957) |
29,498 |
|
-11% |
|
| Kuriyel Ralf |
Senior VP, R&D |
• – – |
2020-12-16 |
4 |
S |
$186.18 |
$80,988 |
D/D |
(435) |
25,654 |
|
-20% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2020-11-19 |
4 |
AS |
$184.69 |
$3,716,051 |
D/D |
(20,000) |
233,327 |
|
4% |
|
| Hunt Anthony |
Chief Executive Officer |
• • – |
2020-11-19 |
4 |
OE |
$26.05 |
$521,000 |
D/D |
20,000 |
253,327 |
|
- |
|
| Ryan Thomas F Jr |
Director |
– • – |
2020-11-11 |
4 |
S |
$187.73 |
$175,340 |
D/D |
(934) |
1,464 |
|
3% |
|
| Ryan Thomas F Jr |
Director |
– • – |
2020-11-11 |
4 |
OE |
$38.76 |
$36,202 |
D/D |
934 |
2,398 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2020-11-10 |
4 |
S |
$193.00 |
$595,598 |
D/D |
(3,086) |
33,455 |
|
-11% |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2020-11-10 |
4 |
OE |
$32.40 |
$99,986 |
D/D |
3,086 |
36,541 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2020-11-09 |
4 |
OE |
$59.52 |
$112,671 |
D/D |
1,893 |
33,455 |
|
- |
|
| Snodgres Jon |
Chief Financial Officer |
• – – |
2020-11-09 |
4 |
S |
$194.69 |
$137,256 |
D/D |
(705) |
31,562 |
|
-8% |
|
647 Records found
|
|
Page 9 of 26 |
|
|
0.91 (0.61%) 
